Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 264
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI | ||
| NCT03077776 | Tracking Triple-negative Breast Cancer Evolution Through Therapy | ||
| NCT07230613 | Neo-adjuvant Immunotherapy in Patients With Localized Melanoma | ||
| NCT00003418 | Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer | ||
| NCT07437287 | Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers | ||
| NCT07106632 | Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests | ||
| NCT00053911 | Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer | ||
| NCT02375204 | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors | ||
| NCT04246606 | Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer | ||
| NCT02117167 | SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | ||
| NCT02400567 | Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women | ||
| NCT00673335 | Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation | ||
| NCT04960735 | Implementation, Effectiveness and Impact of a Value Based Intervention for Patients with Breast or Lung Cancer | ||
| NCT05476796 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer | ||
| NCT00629616 | Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer | ||
| NCT00534274 | Positron Emission Tomography Using 3'-Deoxy-3'-(18F) Fluorothymidine in Treating Women With Locally Advanced Cancer in One Breast Who Are Receiving Chemotherapy | ||
| NCT01564056 | Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment | ||
| NCT06225505 | Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) | ||
| NCT01620242 | A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes | ||
| NCT00002870 | High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer | ||
| NCT03870919 | Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients | ||
| NCT04053322 | Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. | ||
| NCT03246841 | Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes. | ||
| NCT01414933 | High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents | ||
| NCT02444390 | Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor | ||
| NCT01022918 | Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma | ||
| NCT00005979 | Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer | ||
| NCT02980510 | Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients | ||
| NCT03726775 | Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN | ||
| NCT07237256 | Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib | ||
| NCT00820547 | Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients | ||
| NCT00541112 | Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery | ||
| NCT02551237 | Neoadjuvant Treatment for Advanced Rectal Carcinoma | ||
| NCT03013335 | Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen | ||
| NCT03333356 | Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30) | ||
| NCT00104702 | Radiation Therapy in Treating Older Women Who Are Undergoing Surgery for Stage I or Stage II Breast Cancer | ||
| NCT02701907 | EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies | ||
| NCT04790253 | PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) | ||
| NCT05973864 | Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery | ||
| NCT05974774 | Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors | ||
| NCT04725396 | Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC | ||
| NCT00104741 | Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer | ||
| NCT07431073 | Immunotherapy Master Trial for Advanced Cancers | ||
| NCT03386162 | SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer | ||
| NCT04158362 | Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer | ||
| NCT03275311 | Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 | ||
| NCT00103168 | Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor | ||
| NCT02818725 | I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations | ||
| NCT00541008 | Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer | ||
| NCT00217607 | Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery |
